Kyushu Express announced that on December 25, 2025, Huiyuyuanhe Pharmaceutical Co., Ltd., a subsidiary of the subsidiary Beijing Jingfeng Pharmaceutical Group Co., Ltd., received the “Drug Registration Certificate” for promethazine hydrochloride injection approved and issued by the State Drug Administration. Promethazine hydrochloride injection is an antihistamine. It is suitable for mucocutaneous allergies, motion sickness, adjuvant treatment before and after anesthesia, and prevention of radiopathic or drug-induced nausea and vomiting. As of the date of this announcement, Huiyuyuan has invested about RMB 4.67 million in research and development expenses for this drug.

Kyushu Express announced that on December 25, 2025, Huiyuyuanhe Pharmaceutical Co., Ltd., a subsidiary of the subsidiary Beijing Jingfeng Pharmaceutical Group Co., Ltd., received the “Drug Registration Certificate” for promethazine hydrochloride injection approved and issued by the State Drug Administration. Promethazine hydrochloride injection is an antihistamine. It is suitable for mucocutaneous allergies, motion sickness, adjuvant treatment before and after anesthesia, and prevention of radiopathic or drug-induced nausea and vomiting. As of the date of this announcement, Huiyuyuan has invested about RMB 4.67 million in research and development expenses for this drug.